Luca Gianni
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 126 publications
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: March 11, 2026
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 25, 2026
Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.
Journal: NPJ precision oncology
Published: February 03, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: January 28, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 09, 2025
The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms.
Journal: Cell death and differentiation
Published: October 27, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.
Journal: NPJ breast cancer
Published: June 29, 2025
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.
Journal: ESMO open
Published: January 15, 2025
Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer.
Journal: Future oncology (London, England)
Published: September 26, 2024
Two decades of advances in clinical oncology - lessons learned and future directions.
Journal: Nature reviews. Clinical oncology
Published: September 10, 2024
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
Journal: NPJ breast cancer
Published: June 06, 2024
Development and validation of a gene expression-based Breast Cancer Purity Score.
Journal: NPJ precision oncology
Published: March 20, 2024
Last Updated: 09/26/2026